The annual general meeting of Gentian Diagnostics ASA was held on 18 May 2022. All the proposed resolutions on the agenda were approved in accordance with the notice for the meeting, which were published on 27 April 2022.
The minutes of the annual general meeting are enclosed.
The board of directors now consist of 8 members of which the following were re-elected:
Tomas Settevik (Chair)
Espen Tidemann Jørgensen
Kari E. Krogstad
Susanne Stuffers
Tomas Kramar
The following persons were elected as new board members:
Monika Neumann
Monika Neuman has 20 years of experience from the diagnostics industry, currently holding a position as Managing Director for Sarstedt Group in the Nordics. She has previously had several international and commercial leadership roles like Head of Sales, EMEA , and VP Global Business Management. During the past 4 years, Ms Neuman has been working at Siemens Healthineers Laboratory Diagnostics headquarters in Tarrytown, NY, where she was closely collaborating with R&D, Manufacturing, Marketing, and Customer Service to set a successful strategy for launch and implementation of a new product portfolio on the global IVD market.
Ms Neuman holds a MSc degree in Biochemistry and a PhD degree in Clinical Bacteriology from Medical Faculty at Göteborg University in Sweden.
Fredrik Thoresen
Fredrik Thoresen is a partner in Andenaesgruppen where he joined in 2021. Prior to joining Andenaesgruppen, Mr. Thoresen worked as a Portfolio Manager at Storebrand Asset Management and as an Equity Research Analyst at SEB. Mr. Thoresen has also previous buy- and sell-side experience from DNB and Sector Asset Management.
Mr. Thoresen has an MBA in International Business from Middlebury Institute of International Studies, Monterey, California and a bachelor’s degree in Computer Science and Economics from Augustana University, Sioux Falls, South Dakota.
Frank Frantzen
Frank Frantzen has more than 35 years of experience from the diagnostic industry. He has served as principal scientist and has directed larger R&D units in the international IVD companies Axis-Shield, Alere and Abbott. Mr. Frantzen left his Senior Director R&D position at Abbott in 2021 and is currently serving as Chief Technology Officer in CardiNor AS.
Mr. Frantzen holds a master’s degree in chemistry and a Ph.D. in chemistry/biotechnology/IVD-technology, both from the Norwegian University of Science and Technology in Trondheim.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.
GDASA - Minutes of AGM 2022
IR Contact:
Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.com
Cell phone: +47 919 06 525
To see the announcement follow this link: https://newsweb.oslobors.no/message/562510